Future trials in this population could explore personalized dosing strategies as a research question and should be designed to explore strategies that account for individual variability, which may include investigating personalized dose reductions and combination regimens with reno-protective agents (e.g., SGLT-2 inhibitors) to assess the potential for optimizing the benefit-risk ratio (66); Future trials involving CKD patients with comorbidities such as diabetes or hypertension should incorporate rigorous monitoring protocols. The gene discussed is SLC5A2; the disease is diabetes mellitus.